{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/prov/352028104"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/161674922" ] } },

    { "id" : "http://webisa.webdatacommons.org/161674922"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "tering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a denatured collagen type-IV selective antagonist of the invention. [0089] The invention provides a method for inhibiting angiogenesis, tumor growth, metastasis, arthritis, inflammatory diseases and other diseases or conditions associated with cellular interactions with denatured collagen-type-IV in t" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "google.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/24040628"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/161674922" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/318770592"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/161674922" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/436841215"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/161674922" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/423496275"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/161674922" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/443966668"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/161674922"] } } }
